The clinical hold, the histopathological finding, the DARPA failure -- I got out at a profit as these events took place. Then I began wondering, what does COR have going for it -- some evidence in a Phase IIa that it's efficacious in treating ADHD. But will that be borne out in the Phase IIb?
Really, not much has been proven yet as to the efficacy in humans of AMPAKINES. The various compounds may not be the silver bullet I had thought they were before. The future is just unclear, uncertain. It's up in the air as to whether the questions I asked will be answered in the affirmative or the negative.
We are getting the downtick today that I thought we would. I think short-term the slide will continue. As to the longer term, it's just plain uncertain how the AMPAKINE technology, low and high impact, will pan out. So I'm not really negative or positive on COR's future at this point whereas I used to think it was a moonshot waiting to happen. Now I'm just trying to be more realistic, even keel about laying down some serious, hard-earned cash on somewhat of a gamble.
And no, sorry, I don't know what timeframe R&R's price target is for.
Market Data 
Markets 
AI
